



CERTIFICATE OF MAILING  
37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

October 26, 2004

Date

  
Shelley P.M. Fussey

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe and Sophia Ran

Serial No.: 09/351,862

Filed: July 12, 1999

For: CANCER TREATMENT KITS USING  
ANTIBODIES TO  
AMINOPHOSPHOLIPIDS

Group Art Unit: 1617

Examiner: Sharareh, S.

Atty. Dkt. No.: 4001.002282

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the document listed on attached Form PTO-1449 be considered by the Examiner and made of record in the present case. A copy of the listed document required by 37 C.F.R. § 1.98(a)(2) is enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A non-final Official Action on the merits has been received in the present application. However, this Supplemental Information Disclosure Statement is being filed prior to the mailing of a final Official Action, notice of allowance or an Action that closes prosecution, and is timely filed in accordance with 37 C.F.R. § 1.97(c) without a fee in light of the following information.

In accordance with 37 C.F.R. § 1.97(e)(2), it is hereby certified that the document listed on the accompanying Form PTO-1449 was not cited in a communication from a foreign patent office in a counterpart foreign application. The listed document was cited in an Official Action on the merits in a co-pending application of one of the present inventors, Serial No. 09/998,833 (Attorney Docket No. 4001.002299), mailed from the P.T.O. on September 08, 2004, less than three months before the filing of the present statement, and could not have been submitted before receipt.

No fees are due in connection with the filing of this Supplemental Information Disclosure Statement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason, the Examiner should contact the undersigned representative to discuss deduction from Williams, Morgan & Amerson Deposit Account No. 50-0786/4001.002282.

Respectfully submitted,  
Williams, Morgan & Amerson, P.C.  
Customer No. 23720



Shelley P.M. Fussey, Ph.D.  
Reg. No. 39,458  
Agent for Applicants

10333 Richmond, Suite 1100  
Houston, Texas, 77042  
(713) 934-4079

Date: October 26, 2004

Form PTO-1449 (modified)

Atty. Docket No.

4001.002282

Serial No.

09/351,862

List of Patents and Publications for Applicant's

Applicant

Thorpe and Ran

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

July 12, 1999

Group:

1617

U.S. Patent Documents

See Page

Foreign Patent Documents

See Page

Other Art

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C119	Tschmelitsch <i>et al.</i> , "Enhanced Antitumor Activity of Combination Radioimmunotherapy ( <sup>131</sup> I-Labeled Monoclonal Antibody A33) with chemotherapy (Fluorouracil)," <i>Cancer Res.</i> , 57:3181-3186, 1197.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

4001.002282

Serial No.

09/351,862

List of Patents and Publications for Applicant's

Applicant

Thorpe and Ran

INFORMATION DISCLOSURE STATEMENT

Filing Date:

July 12, 1999

Group:

1617

(Use several sheets if necessary)

U.S. Patent Documents

See Page

Foreign Patent Documents

See Page

Other Art

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C111	Ben-Hur and Orenstein, "The Endothelium and Red Blood Cell as Potential Targets in PDT-Induced Vascular Stasis," <i>J. Radiat. Biol.</i> , 60(1/2):293-301, 1991.
	C112	Folkman, "Tumor Angiogenesis," <i>Adv. Cancer Res.</i> , 43:175-203, 1985.
	C113	Gschwind <i>et al.</i> , "The Discovery of Receptor Tyrosine Kinases: Targets for Cancer Therapy," <i>Nature Reviews/Cancer</i> , 4:361-370, 2004.
	C114	Martiny-Baron and Marmé, "VEGF-Mediated Tumour Angiogenesis: A New Target for Cancer Therapy," <i>Curr. Opin. Biotech.</i> , 6:675-680, 1995.
	C115	McDonald and Baluk, "Significance of Blood Vessel Leakiness in Cancer," <i>Cancer Research</i> , 62:5381-5385, 2002.
	C116	Murata <i>et al.</i> , "Immunohistochemical Detection of Extravasated Fibrinogen (Fibrin) in Human Diabetic Retina," <i>Graefe's Arch. Clin. Exp. Ophthalmol.</i> , 230:428-431, 1992.
	C117	Risau, "What, if anything, is an Angiogenic Factor?" <i>Cancer Metastasis Rev.</i> , 15:149-151, 1996.
	C118	Wiig <i>et al.</i> , "Interstitial Fluid Pressure in DMBA-Induced Rat Mammary Tumours," <i>Scand. J. Clin. Lab. Invest.</i> , 42:159-164, 1982.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

